Summary： The specimens of ductal carcinoma in situ （DCIS） with early invasion, and specimens col- lected by core needle biopsy （CNB） tend to contain limited amount of invasive component, so it is im- perative to ...Summary： The specimens of ductal carcinoma in situ （DCIS） with early invasion, and specimens col- lected by core needle biopsy （CNB） tend to contain limited amount of invasive component, so it is im- perative to explore a new technique which can assess HER2 gene status accurately for the limited inva- sive cancer component in these specimens. Dual staining technique of combining immunohistochemis- try （IHC） for myoepithelial cells and single or dual probe chromogenic in situ hybridization （CISH） for HER2 gene was performed on routinely processed paraffin sections from 20 cases diagnosed as having DCIS with invasive cancer. Among them, 10 had fluorescence in situ hybridization （FISH）-confirmed amplification of HER2 and 10 had FISH-confirmed non-amplification of HER2. We successfully de- tected HER2 genetic signals and myoepithelial IHC markers （SMM-HC or CK5/6） simultaneously on a single section in all 20 specimens. Myoepithelial markers and HER2 signals detected by dual staining assay were consistent with those by individual technique performed alone. HER2 gene amplification results determined by dual staining assay were 100% consistent with those of FISH. Dual staining tech- nique which allows simultaneous detection of myoepithelial marker protein and cancerous HER2 gene is feasible, and it has potential to be used in clinical practice for effective determination of HER2 ampli- fication in limited invasive component.展开更多
目的探讨用免疫组化(immunohistochemistry,IHC)和显色原位杂交技术(chromogenic in situ hybridization,CISH)检测乳腺癌HER-2蛋白表达和基因扩增在临床病理诊断及分子靶向治疗中的应用及意义。方法用免疫组化(IHC)和显色原位杂交技术(...目的探讨用免疫组化(immunohistochemistry,IHC)和显色原位杂交技术(chromogenic in situ hybridization,CISH)检测乳腺癌HER-2蛋白表达和基因扩增在临床病理诊断及分子靶向治疗中的应用及意义。方法用免疫组化(IHC)和显色原位杂交技术(CISH)检测60例乳腺癌石蜡包埋组织标本中HER-2蛋白的表达及基因扩增情况,比较两种方法的结果以及与临床病理的关系。结果 HER-2蛋白过表达与HER-2基因扩增之间密切相关。结论两者综合结果的判定对乳腺癌患者的临床治疗有明确的指导意义,可用于临床赫塞汀(Herceptin)分子靶向治疗病例的筛选。展开更多
AIM:To assess human epidermal growth factor receptor-2 (HER2)-status in gastric cancer and matched lymph node metastases by immunohistochemistry (IHC) and chromogenic in situ hybridization (CISH).METHODS:120 cases of ...AIM:To assess human epidermal growth factor receptor-2 (HER2)-status in gastric cancer and matched lymph node metastases by immunohistochemistry (IHC) and chromogenic in situ hybridization (CISH).METHODS:120 cases of primary gastric carcinomas and 45 matched lymph node metastases from patients with full clinicopathological features were mounted onto multiple-punch and single-punch tissue microarrays,respectively,and examined for HER2 overexpression and gene amplification by IHC and CISH.RESULTS:Twenty-four tumors (20%) expressed HER2 immunohistochemically.An IHC score of ≥ 2+ was observed in 20 tumors (16.6%).HER2 amplification was detected by CISH in 19 tumors (15.8%) and in their matched lymph node metastases.A high concordancerate was found between HER2 positivity (as detected by IHC) and HER2 gene amplification (as detected by CISH),since 19 of the 20 IHC positive cases were amplified (95%).All amplified cases had 2+ or 3+ IHC results.Amplification was associated with intestinal phenotype (P < 0.05).No association with grading,staging or survival was found.CONCLUSION:In gastric cancer,HER2 amplification is the main mechanism for HER2 protein overexpression and is preserved in lymph node metastases.展开更多
基金supported by grants from the Natural Science Foundation of Hubei Province (No. 2008CDB152)Science and Technology Foundation of Hubei Province (No.2007AA402A40)
文摘Summary： The specimens of ductal carcinoma in situ （DCIS） with early invasion, and specimens col- lected by core needle biopsy （CNB） tend to contain limited amount of invasive component, so it is im- perative to explore a new technique which can assess HER2 gene status accurately for the limited inva- sive cancer component in these specimens. Dual staining technique of combining immunohistochemis- try （IHC） for myoepithelial cells and single or dual probe chromogenic in situ hybridization （CISH） for HER2 gene was performed on routinely processed paraffin sections from 20 cases diagnosed as having DCIS with invasive cancer. Among them, 10 had fluorescence in situ hybridization （FISH）-confirmed amplification of HER2 and 10 had FISH-confirmed non-amplification of HER2. We successfully de- tected HER2 genetic signals and myoepithelial IHC markers （SMM-HC or CK5/6） simultaneously on a single section in all 20 specimens. Myoepithelial markers and HER2 signals detected by dual staining assay were consistent with those by individual technique performed alone. HER2 gene amplification results determined by dual staining assay were 100% consistent with those of FISH. Dual staining tech- nique which allows simultaneous detection of myoepithelial marker protein and cancerous HER2 gene is feasible, and it has potential to be used in clinical practice for effective determination of HER2 ampli- fication in limited invasive component.
文摘目的探讨用免疫组化(immunohistochemistry,IHC)和显色原位杂交技术(chromogenic in situ hybridization,CISH)检测乳腺癌HER-2蛋白表达和基因扩增在临床病理诊断及分子靶向治疗中的应用及意义。方法用免疫组化(IHC)和显色原位杂交技术(CISH)检测60例乳腺癌石蜡包埋组织标本中HER-2蛋白的表达及基因扩增情况,比较两种方法的结果以及与临床病理的关系。结果 HER-2蛋白过表达与HER-2基因扩增之间密切相关。结论两者综合结果的判定对乳腺癌患者的临床治疗有明确的指导意义,可用于临床赫塞汀(Herceptin)分子靶向治疗病例的筛选。
文摘AIM:To assess human epidermal growth factor receptor-2 (HER2)-status in gastric cancer and matched lymph node metastases by immunohistochemistry (IHC) and chromogenic in situ hybridization (CISH).METHODS:120 cases of primary gastric carcinomas and 45 matched lymph node metastases from patients with full clinicopathological features were mounted onto multiple-punch and single-punch tissue microarrays,respectively,and examined for HER2 overexpression and gene amplification by IHC and CISH.RESULTS:Twenty-four tumors (20%) expressed HER2 immunohistochemically.An IHC score of ≥ 2+ was observed in 20 tumors (16.6%).HER2 amplification was detected by CISH in 19 tumors (15.8%) and in their matched lymph node metastases.A high concordancerate was found between HER2 positivity (as detected by IHC) and HER2 gene amplification (as detected by CISH),since 19 of the 20 IHC positive cases were amplified (95%).All amplified cases had 2+ or 3+ IHC results.Amplification was associated with intestinal phenotype (P < 0.05).No association with grading,staging or survival was found.CONCLUSION:In gastric cancer,HER2 amplification is the main mechanism for HER2 protein overexpression and is preserved in lymph node metastases.
